Blueprint Medicines Corporation Stock News

CAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Daniella Beckman to its board of directors. Ms. Beckman, who is currently the Chief Financial Officer of Tango Therapeutics and board member for Vor Biopharma

Blueprint Medicines could pay an additional $215 million if Lengo''s experimental treatment hits regulatory and sales targets.

HC Wainwright restated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC) in a report released on Tuesday morning, Price Targets.com reports. They currently have a $134.00 price objective on the biotechnology companys stock. Several other equities analysts have also recently commented on BPMC. TheStreet cut shares of Blueprint Medicines from a c rating to []

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a

Assenagon Asset Management S.A. lowered its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 6.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 246,151 shares of the biotechnology companys stock after selling 16,108 shares during the quarter. Assenagon Asset Management S.A. owned about []

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

Analysts predict that Blueprint Medicines Co. (NASDAQ:BPMC) will report sales of $100.27 million for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Blueprint Medicines earnings, with the lowest sales estimate coming in at $92.95 million and the highest estimate coming in at $105.00 million. Blueprint Medicines posted sales of $34.11 []

Blueprint Medicines Co. (NASDAQ:BPMC) Stock analysts at Wedbush dropped their FY2025 earnings per share estimates for shares of Blueprint Medicines in a research report issued on Monday, November 29th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of $4.53 for the year, down from their prior forecast []

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.

Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.